Laura K. Schnackenberg Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
ARA Fellow
faculty
laura.schnackenberg@fda.hhs.gov
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Laura K. Schnackenberg's research focuses on understanding drug-induced liver injury and developing predictive biomarkers for patient outcomes. Her work utilizes advanced techniques such as mass spectrometry imaging and metabolomics to identify molecular signatures associated with toxicity and recovery. Schnackenberg has investigated the effects of specific compounds, like the tire rubber antiozonant 6PPD and its transformation product 6PPD-quinone, on primary human hepatocytes and liver spheroids.
Her research extends to evaluating novel therapeutic strategies and diagnostic tools. This includes exploring the potential of co-culturing human primary hepatocytes and nonparenchymal liver cells in liver-on-a-chip platforms to study drug-induced liver injury and developing methods to measure relevant biomarkers within these systems. Schnackenberg also contributes to the broader field of toxicology by studying mitochondrial dysfunction in hepatocytes caused by compounds like Pexidartinib and investigating cardiotoxicity prediction using induced pluripotent stem cell-derived cardiomyocytes.
Schnackenberg's scholarship metrics include an h-index of 34, 87 total publications, and 3,509 total citations. She maintains collaborations with researchers at the National Center for Toxicological Research, including Katy S Papineau and Lijun Ren, with whom she has co-authored multiple publications. She leads a research group and maintains an active lab website.
Metrics
- h-index: 34
- Publications: 87
- Citations: 3,520
Selected Publications
-
Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform (2025)
-
Toxicity of ubiquitous tire rubber antiozonant N-(1,3-dimethylbutyl)-N′-phenyl-p-phenylenediamine (6PPD) and its transformation product 6PPD-quinone (6PPD-Q) in primary human hepatocytes and liver spheroids (2025)
-
Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations (2025)
-
Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin (2024)
-
Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury (2022)
-
Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy (2021)
-
Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients (2021)
-
MALDI imaging mass spectrometry: an emerging tool in neurology (2021)
ARA Academy 2021 ARA Fellow
Dr. Schnackenberg's work centers on applying advanced analytical chemistry to toxicology and drug safety. From 2003-2019, she focused on NMR metabolomics to evaluate drug toxicity mechanisms. She subsequently adopted MALDI imaging mass spectrometry techniques. As Branch Chief, she directs projects including drug-induced hepatotoxicity biomarker evaluation, patient-specific cell line responses to tyrosine kinase inhibitors, and novel mass spectrometry tools for bacterial and viral identification.
Policy Impact
Directs FDA research programs advancing drug safety evaluation and mass spectrometry tools for pathogen identification, strengthening Arkansas's federal research presence.
Growth Areas
['Population Health Innovations & Clinical Research']
Collaboration Network
Top Collaborators
- Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- Toxicity of ubiquitous tire rubber antiozonant N-(1,3-dimethylbutyl)-N′-phenyl-p-phenylenediamine (6PPD) and its transformation product 6PPD-quinone (6PPD-Q) in primary human hepatocytes and liver spheroids
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- Toxicity of ubiquitous tire rubber antiozonant N-(1,3-dimethylbutyl)-N′-phenyl-p-phenylenediamine (6PPD) and its transformation product 6PPD-quinone (6PPD-Q) in primary human hepatocytes and liver spheroids
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- Toxicity of ubiquitous tire rubber antiozonant N-(1,3-dimethylbutyl)-N′-phenyl-p-phenylenediamine (6PPD) and its transformation product 6PPD-quinone (6PPD-Q) in primary human hepatocytes and liver spheroids
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- MALDI imaging mass spectrometry: an emerging tool in neurology
- Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
Similar Researchers
Based on overlapping research topics